Company news
Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) news
Indivior Pharmaceuticals, Inc. news releases on 6ix. Latest, Oct 30, 2024: Indivior Highlights Growing Body of Data on SUBLOCADE® (buprenorphine once-monthly…
Press releases — page 2
Indivior Highlights Growing Body of Data on SUBLOCADE® (buprenorphine once-monthly extended-release injection) Helping Patients Achieve Long-Term Recovery from Opioid Use Disorder during Substance Abuse Prevention Month
October 29, 2024
Indivior Announces Q3 2024 Financial Results
October 23, 2024
Indivior Provides Preliminary Q3 2024 Results; Updates FY 2024 Guidance; Group Continues to Expect SUBLOCADE Peak Net Revenue of >$1.5 Billion
October 9, 2024
Indivior's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review
October 6, 2024
Indivior Provides Update on Aelis Farma's Clinical Phase 2B Study Results with AEF0117 in Participants with Cannabis Use Disorder
September 3, 2024
Indivior Announces BARDA's First Order of OPVEE® to Combat Opioids and Aid in National Preparedness
August 25, 2024
Indivior Announces Q2 2024 Financial Results
July 24, 2024
Indivior Announces a New $100 Million Share Repurchase Program; New Program will be Executed Over an Accelerated Time Frame
July 24, 2024
Indivior Provides Business Update; Conference Call at 8:00 AM U.S. EDT
July 8, 2024
Indivior Announces the Publication of New Data on the Comparative Effectiveness of Intranasal (IN) Nalmefene (OPVEE 2.7mg) and IN Naloxone (4 mg) in a Translational Model Assessing the Impact of a Synthetic Opioid Overdose on Respiratory Depression an...
June 17, 2024
Indivior Announces Dosing of First Subject with INDV-2000 in a Phase 2 Study Assessing the Safety and Efficacy of INDV-2000 in Individuals with Opioid Use Disorder
June 9, 2024
Indivior Announces Q1 2024 Financial Results
April 24, 2024
Indivior Announces Publication Demonstrating that OPVEE® (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal Naloxone
March 10, 2024
Indivior Announces Q4 / FY 2023 Financial Results
February 21, 2024
Indivior Announces Q3 2023 Financial Results
November 8, 2023
Indivior Enters an Exclusive Licensing Agreement with Alar Pharmaceuticals
October 10, 2023
Indivior Publishes Real World Data Showing SUBLOCADE® May Reduce Non-Fatal Overdoses Among Individuals with Opioid Use Disorder in Canada
September 25, 2023
Indivior Reaches Agreement with End Payor Class to Resolve Their Antitrust Multi-District Litigation Claims
August 20, 2023
Indivior Announces Q2/H1 2023 Financial Results
July 26, 2023
Indivior Announces Four Abstracts Accepted for Presentation at the 85th Annual Scientific Meeting of the College on Problems of Drug Dependence
June 13, 2023